Deramciclane in the treatment of generalized anxiety disorder: A placebo-controlled, double-blind, dose-finding study

@article{Naukkarinen2005DeramciclaneIT,
  title={Deramciclane in the treatment of generalized anxiety disorder: A placebo-controlled, double-blind, dose-finding study},
  author={Hannu Naukkarinen and Roope Raassina and Jukka Penttinen and Antti Ahokas and Riitta Jokinen and Hannu Koponen and Ulla M. Lepola and Harri Kanerva and Leena Lehtonen and Tiina Pohjalainen and Auli Partanen and Outi M{\"a}ki-Ikola and Juha Rouru},
  journal={European Neuropsychopharmacology},
  year={2005},
  volume={15},
  pages={617-623}
}

Non-Antidepressant Treatment of Generalized Anxiety Disorder.

TLDR
Pregabalin and quetiapine are the two most promising non-antidepressant treatments for GAD.

Effect of the novel anxiolytic drug deramciclane on cytochrome P450 2D6 activity as measured by desipramine pharmacokinetics

TLDR
Although deramciclane seems to be a weaker inhibitor of CYP2D6 than paroxetine, dose adjustment of drugs metabolized by CYP 2D6 may be needed when used concomitantly with deram ciclane.

Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone

TLDR
Deramciclane does not inhibit CYP3A4 activity as measured by buspirone pharmacokinetics, and there were no indications of relevant pharmacodynamic interaction after multiple doses of deramcIClane and a single dose of buspir one.

Agomelatine improves symptoms of generalised anxiety disorder

TLDR
Primary outcome: overall anxiety (HAM-A). Secondary outcomes: response (?50% reduction in HAM-A score) and discontinuation effects in the week after discontinuation (Discontinuation Emergent Signs and Symptoms scale (DESS).

Advances in the Management of Treatment-Resistant Anxiety Disorders

TLDR
The evidence for possible medication, psychotherapy, brain stimulation, and neurosurgical approaches—including some promising novel treatments—for managing treatment-resistant anxiety is reviewed.

Recent developments in anxiety disorders.

TLDR
The areas of current interest and possible future development of anxiolytic drugs by outlining recent patents in this field are described and grouped into neurotransmitter systems for an overview of recent developments in the neuropharmacology of anxiety disorders.

Identifying HAM‐A cutoffs for mild, moderate, and severe generalized anxiety disorder

TLDR
The proposed cutoffs for mild, moderate, and severe ranges of Hamilton Anxiety Rating Scale (HAM‐A) scores could make results more meaningful and interpretable for researchers, clinicians, and patients if accepted for general use.

The role of the serotonergic and GABA system in translational approaches in drug discovery for anxiety disorders

TLDR
It is argued that, in addition to human genetic studies, translational models are essential to map anxiety-related genes and to enhance the understanding of anxiety disorders in order to develop potentially novel treatment strategies.

References

SHOWING 1-10 OF 28 REFERENCES

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.

TLDR
Paroxetine in doses of 20 to 50 mg once daily is effective in the treatment of patients with GAD and is associated with significant reduction in disability after only 8 weeks of treatment.

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.

TLDR
Venlafaxine XR is an effective, safe, and well-tolerated once-daily anxiolytic agent in patients with GAD without comorbid major depressive disorder.

Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data.

  • D. Sheehan
  • Psychology
    The Journal of clinical psychiatry
  • 2001
TLDR
The results of these studies demonstrate the strong potential of venlafaxine XR in facilitating remission in GAD, with a substantial effect size in the individual HAM-A items of worry, anxiety, and behavior at interview.

Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms.

TLDR
In generalized anxiety, somatic symptoms and hyperarousal selectively respond to drugs acting on the gamma-aminobutyric acid system, whereas psychic symptoms respond to treatments affecting the noradrenergic or serotonergic systems.

Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder.

TLDR
The HAM-A and BSA items that most closely corresponded to DSM-IV diagnostic criteria for GAD showed the largest improvement during treatment with venlafaxine XR, indicating that the specific symptoms of GAD can be treated effectively with ven lafaxines extended release, both in the short and longer term.

Paroxetine efficacy in the treatment of generalized anxiety disorder

TLDR
Paroxetine and imipramine affect predominantly psychic symptoms, whereas 2′‐chlordesmethyldiazepam affects predominantly somatic symptoms, and the results suggest that paroxetines is effective for the treatment of GAD.

Analysis of individual symptoms in generalized anxiety--a pooled, multistudy, double-blind evaluation of buspirone.

TLDR
Analysis of data for 427 patients with generalized anxiety disorders analyzed retrospectively from six double-blind trials indicated that all of the 14 symptom groups, the total HAM-A score, and the 2 composite Psychic and Somatic Anxiety Factors were significantly improved with buspirone as compared to placebo.

Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety Disorder

TLDR
All doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses, and the discontinuation rate did not differ significantly among the treatment groups.

Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder.

  • J. Ballenger
  • Psychology, Biology
    The Journal of clinical psychiatry
  • 2001
TLDR
Preclinical and clinical data supporting the role of GABA, 5-HT, and NE in the pathophysiology of GAD and the pharmacotherapeutic agents that modulate these neurotransmitter systems and have been proved efficacious in reducing the symptoms associated with GAD are summarized.

New concepts in anxiety

TLDR
Anxiety and its therapy - today and tomorrow, D.Nutt the neuropsychology of anxiety and stress, J.W.Curran anxiety and cognition, R.V.Lister cognitive factors in clinical anxiety - potential relevance to therapy, M.G.Grahame-Smith the role of serotonin in anxiety - behavioural approaches.